Significant progress has been made globally by various investigators, laboratories, and pharmaceutical companies in understanding the hormonal regulation of BPH, with LH-RH and GH-RH analogs emerging as promising therapeutic options (Fig. 2 and Box 3). The gene discussed is GNRH1; the disease is benign prostatic hyperplasia.